Skip to Content

Amicar (aminocaproic acid) Disease Interactions

There are 3 disease interactions with Amicar (aminocaproic acid):

Major

Aminocaproic Acid (Includes Amicar) ↔ Myopathy

Severe Potential Hazard, Low plausibility

Applies to: Myopathy

Skeletal muscle toxicity ranging from mild myalgia to rhabdomyolysis has been reported rarely during prolonged administration of aminocaproic acid. Therapy with aminocaproic acid should be administered cautiously in patients with or predisposed to myopathy. Clinical monitoring of muscle enzymes (particularly CPK) are recommended.

References

  1. "Product Information. Amicar (aminocaproic acid)." Immunex Corporation, Seattle, WA.
Major

Aminocaproic Acid (Includes Amicar) ↔ Renal Dysfunction

Severe Potential Hazard, High plausibility

Applies to: Renal Dysfunction

Aminocaproic acid is primarily eliminated by the kidney. Approximately 65% of aminocaproic acid is excreted unchanged in the urine. Serum concentrations of aminocaproic acid can be increased in patients with renal impairment. Therapy with aminocaproic acid should be administered with extreme caution in patients with upper urinary tract bleeding. Glomerular capillary thrombosis or clots in the renal pelvis and ureters have occurred in patients with upper urinary tract bleeding during aminocaproic acid therapy. Clinical monitoring of renal function, clot lysis activity and fibrinolytic determinants (profibrinolysin, fibrinolysin and anti-fibrinolysin) is recommended.

References

  1. "Product Information. Amicar (aminocaproic acid)." Immunex Corporation, Seattle, WA.
Major

Aminocaproic Acid (Includes Amicar) ↔ Thrombohemorrhagic Disorders

Severe Potential Hazard, High plausibility

Applies to: Thrombotic/Thromboembolic Disorder, Disseminated Intravascular Coagulation

The use of aminocaproic acid is contraindicated in patients with active intravascular clotting. Aminocaproic acid should not be used in the presence of disseminated intravascular coagulation (DIC) without concomitant administration of heparin. Aminocaproic acid inhibits plasminogen activators and, to a lesser extent, plasmin activity, resulting in decreased fibrinolysis. Clinical monitoring of clot lysis activity and fibrinolytic determinants (profibrinolysin, fibrinolysin and anti-fibrinolysin) is recommended.

References

  1. "Product Information. Amicar (aminocaproic acid)." Immunex Corporation, Seattle, WA.

Amicar (aminocaproic acid) drug Interactions

There are 12 drug interactions with Amicar (aminocaproic acid)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2018 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide